Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers
Home › MI › WEST BLOOMFIELD › ORCHARD LABORATORIES CORP

ORCHARD LABORATORIES CORP

NPI: 1932507969 · WEST BLOOMFIELD, MI 48322 · Clinical Medical Laboratory · NPI assigned 12/08/2014

$25.29M
Total Medicaid Paid
515,927
Total Claims
437,649
Beneficiaries
147
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialAHMAD, SAMI (PRESIDENT)
NPI Enumeration Date12/08/2014

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 11,657 $1.23M
2019 17,830 $2.14M
2020 67,334 $5.79M
2021 179,987 $9.28M
2022 130,861 $4.97M
2023 73,414 $1.87M
2024 34,844 $735.20

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 147,361 118,871 $10.17M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 57,642 50,093 $7.46M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 24,187 21,387 $2.15M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 97,926 86,445 $1.87M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 6,455 6,308 $665K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 13,417 6,137 $648K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 9,654 7,277 $539K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 16,185 13,180 $312K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 1,551 1,531 $241K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 7,745 5,298 $108K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 4,192 3,748 $92K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 4,659 3,967 $89K
87481 5,408 5,074 $76K
86769 1,597 899 $73K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 5,419 5,274 $69K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 5,320 4,887 $61K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 5,318 5,179 $59K
87653 4,053 3,862 $54K
80053 Comprehensive metabolic panel 8,098 7,113 $43K
87640 2,212 2,132 $34K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 2,985 2,944 $30K
84443 Thyroid stimulating hormone (TSH) 4,392 4,246 $30K
85004 5,680 4,379 $25K
80061 Lipid panel 4,339 4,242 $22K
87563 2,097 2,042 $22K
86328 636 636 $20K
87529 702 684 $20K
87511 2,101 2,047 $19K
87581 1,290 1,268 $18K
83036 Hemoglobin; glycosylated (A1C) 4,510 4,366 $18K
87486 1,275 1,251 $18K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 884 867 $17K
87631 553 550 $15K
80048 Basic metabolic panel (calcium, ionized) 2,400 1,844 $13K
87806 1,414 1,402 $13K
82607 2,177 2,127 $11K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 1,300 1,228 $10K
81514 325 319 $9K
86804 1,462 1,439 $8K
86409 136 136 $7K
82652 331 315 $7K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2,603 2,421 $6K
86705 1,066 1,048 $5K
85027 1,641 1,311 $5K
86709 1,082 1,064 $5K
82746 1,123 1,116 $5K
K1034 Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count 5,081 4,698 $5K
87498 322 308 $5K
87186 1,315 735 $5K
83735 1,319 1,218 $4K
86696 584 581 $4K
87541 226 220 $4K
84439 1,515 1,482 $4K
87340 860 847 $4K
84134 337 319 $3K
80164 301 249 $3K
80177 302 282 $3K
86695 587 584 $3K
81003 3,111 2,978 $3K
83540 1,070 1,042 $2K
87634 320 304 $2K
84153 436 434 $2K
36415 Collection of venous blood by venipuncture 8,881 6,192 $2K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 188 175 $2K
80370 54 28 $2K
84402 147 140 $2K
84480 316 308 $2K
80326 51 25 $2K
87641 86 85 $1K
82728 357 346 $1K
83718 484 482 $1K
83550 329 311 $1K
84460 566 563 $1K
84450 558 555 $975.67
84403 69 64 $946.67
86140 343 256 $931.31
84100 313 282 $907.77
80361 55 29 $844.19
83992 194 153 $814.86
80348 98 58 $748.78
80365 55 29 $748.78
G2024 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source 543 408 $717.52
80354 55 28 $695.13
80356 82 41 $695.13
80373 54 28 $695.13
80349 80 40 $695.13
85652 400 327 $635.07
80358 54 28 $628.14
82550 173 160 $621.19
80353 82 42 $582.90
80360 52 26 $526.93
80366 36 12 $526.93
80368 53 26 $526.93
80355 53 27 $510.11
82043 555 549 $503.32
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A 179 177 $475.15
84075 357 354 $464.75
84466 70 70 $445.17
80345 53 27 $440.51
80076 228 223 $410.12
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 16 16 $398.18
82172 13 13 $349.20
85611 159 87 $321.37
85610 143 74 $298.98
84550 201 200 $296.58
80202 40 14 $260.38
82565 178 145 $235.45
87086 Culture, bacterial; quantitative colony count, urine 1,003 986 $228.52
84481 82 82 $196.42
84436 217 208 $156.86
82977 40 40 $145.10
84702 14 13 $137.17
83625 13 13 $127.08
84520 143 132 $124.64
86780 389 383 $120.01
86141 78 78 $118.03
86803 13 13 $116.81
84311 50 50 $115.00
82248 31 31 $87.36
82570 242 240 $82.02
86038 12 12 $80.42
87804 Infectious agent antigen detection by immunoassay; Influenza, each type 12 12 $79.52
81001 43 38 $79.24
84154 12 12 $60.92
83986 50 50 $50.73
85730 13 12 $39.84
82947 102 101 $39.12
82247 88 88 $0.00
80074 281 274 $0.00
87501 82 75 $0.00
80338 15 12 $0.00
84295 91 90 $0.00
80346 32 28 $0.00
80375 16 13 $0.00
80372 19 16 $0.00
84155 89 89 $0.00
82310 89 88 $0.00
82465 85 85 $0.00
82374 88 87 $0.00
80364 15 13 $0.00
82435 89 88 $0.00
87070 96 95 $0.00
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 271 268 $0.00
82040 88 88 $0.00
80329 16 13 $0.00
84478 86 86 $0.00
84132 90 89 $0.00